// App-Quantinova.ai

BSH19‐EP‐068 : Feasibility, safety and efficacy of concomitant ponatinib with apixaban, as prophylaxis for arterial and venous thrombosis in patients with chronic myeloid leukaemia (CML) pre‐ and post‐allogeneic stem cell transplantation.

Researchers

Presenter

  • J. Schofield

Principal Investigators

  • K. Knight

  • R. Salim

  • A. Patel

Medical Centers

  • Stem Cell Transplantation and Cellular Therapy Unit, The Clatterbridge Cancer Centre NHS Foundation Trust

  • University of Liverpool, Liverpool, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

  • Ph chromosome

Drug/Treatment

  • Ponatinib

  • apixaban

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved